Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Rectal Neoplasms × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Fallopian Tube Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumors 1

Interventions

Fluorouracil 20 Oxaliplatin 17 Leucovorin 17 Bevacizumab 16 Panitumumab 12 Irinotecan 12 Cetuximab 11 IFL protocol 9 Capecitabine 9 pembrolizumab 7 Radiotherapy 7 Pemetrexed 5 Gemcitabine 5 labetuzumab 3 conatumumab 3 Cisplatin 3 Carboplatin 3 Albumin-Bound Paclitaxel 3 130-nm albumin-bound paclitaxel 3 trametinib 2 spartalizumab 2 pegfilgrastim 2 ganitumab 2 encorafenib 2 dostarlimab 2 Ramucirumab 2 Paclitaxel 2 Melphalan 2 Levoleucovorin 2 Immunoconjugates 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡